07.07.14
The University of Utah’s Huntsman Cancer Institute (HCI) has been established as a training center for BSD Medical Corporation’s MicroThermX microwave ablation system (MicroThermX). HCI will provide training on the microwave ablation treatments using the MicroThermX for physicians throughout the United States. As part of the training, physicians will be able to observe microwave ablation treatments using the MicroThermX at HCI. HCI physicians will also provide consulting services and serve as a resource center for information on microwave ablation treatments using the MicroThermX.
“We are excited to have this prestigious cancer center agree to serve as a teaching center and a Center of Excellence for the MicroThermX,” said Harold Wolcott, president of BSD Medical. “Setting up teaching centers throughout the United States is part of BSD’s comprehensive marketing strategy to build the network of physicians using the MicroThermX and thus increase BSD’s market share. HCI will serve as a comprehensive resource and training center for academic and clinical training on microwave ablation treatments using the MicroThermX for both current and future physicians and researchers.”
The HCI is part of the University of Utah Health Care system. It is a National Cancer Institute-Designated Cancer Center, which means it meets the highest standards for cancer care and research and receives support for its scientific endeavors. HCI is also a member of the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of the world’s leading cancer centers. NCCN is dedicated to improving the quality and effectiveness of care provided to patients with cancer. HCI serves thousands of cancer patients throughout the Intermountain West region every year and provides academic and clinical training for future physicians and researchers.
The MicroThermX is marketed as a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. It is designed to allow delivery of higher power levels using a single generator.
The MicroThermX uses synchronous phased array technology that was developed and patented by MicroThermX BSD to provide a wide range of uniform zones of ablation. The system includes disposables (SynchroWave antennas) for use in each ablation treatment.
The soft tissue tumor ablation world market potential is estimated to exceed $2.3 billion. BS has both U.S. Food and Drug Administration 510(k) clearance and the European CE mark to market the MicroThermX for ablation of soft tissue.
Based in Salt Lake City, Utah, BSD Medical makes systems to treat cancer and benign diseases using heat therapy delivered using focused microwave energy and radiofrequency.
“We are excited to have this prestigious cancer center agree to serve as a teaching center and a Center of Excellence for the MicroThermX,” said Harold Wolcott, president of BSD Medical. “Setting up teaching centers throughout the United States is part of BSD’s comprehensive marketing strategy to build the network of physicians using the MicroThermX and thus increase BSD’s market share. HCI will serve as a comprehensive resource and training center for academic and clinical training on microwave ablation treatments using the MicroThermX for both current and future physicians and researchers.”
The HCI is part of the University of Utah Health Care system. It is a National Cancer Institute-Designated Cancer Center, which means it meets the highest standards for cancer care and research and receives support for its scientific endeavors. HCI is also a member of the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of the world’s leading cancer centers. NCCN is dedicated to improving the quality and effectiveness of care provided to patients with cancer. HCI serves thousands of cancer patients throughout the Intermountain West region every year and provides academic and clinical training for future physicians and researchers.
The MicroThermX is marketed as a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. It is designed to allow delivery of higher power levels using a single generator.
The MicroThermX uses synchronous phased array technology that was developed and patented by MicroThermX BSD to provide a wide range of uniform zones of ablation. The system includes disposables (SynchroWave antennas) for use in each ablation treatment.
The soft tissue tumor ablation world market potential is estimated to exceed $2.3 billion. BS has both U.S. Food and Drug Administration 510(k) clearance and the European CE mark to market the MicroThermX for ablation of soft tissue.
Based in Salt Lake City, Utah, BSD Medical makes systems to treat cancer and benign diseases using heat therapy delivered using focused microwave energy and radiofrequency.